Trump's ‘Liberation Day' tariffs halted by Court of International Trade
The Court of International Trade ruled Wednesday that President Donald Trump exceeded his authority in imposing tariffs on all imported goods, calling an immediate halt to his signature trade war policy.
'The challenged Tariff Orders will be vacated and their operation permanently enjoined,' a three-judge panel ruled.
Even before the decision, the White House vowed to appeal an unfavorable decision.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Residential solar installer Sunnova files for bankruptcy, plans to sell and wind down operations
This story was originally published on Utility Dive. To receive daily news and insights, subscribe to our free daily Utility Dive newsletter. Sunnova, the second-largest installer of third-party owned residential solar installations by market share, filed for chapter 11 bankruptcy on Sunday. Although the company's customer base and revenue continued to grow, rising interest rates, inflation, tariffs and other factors had eroded the company's profit margins, rendering it unable to pay its debts, President and CEO Paul Mathews said in the bankruptcy filings. Sunnova plans to sell off 'substantially all' of the company's assets and wind-down any remaining operations following the sale, Mathews said. Sunnova said in a Monday announcement following the filing that it will accept bids on its assets and business operations for the next 45 days; after the sale, the company plans to wind-down any remaining operations and close, Mathews said in court filings. The company has already agreed to sell some assets to a holding company that has received $15 million in financing from global investment firm ATLAS SP Partners, and has also agreed to sell other assets from its new homes business unit to builder Lennar Homes for $16 million, according to the company announcement. 'Today's actions mark a critical step towards securing a value-maximizing outcome for Sunnova's stakeholders,' Mathews said in a statement Monday. 'Throughout this process, maintaining continuity of service for our customers is our top priority as we work to secure a long-term solution for our business operations under new ownership.' Matthews said he was 'incredibly grateful to our dedicated Sunnova team for their hard work and commitment. We have built an innovative power provider, and I continue to believe deeply in the future of our industry and the promise of residential solar and storage.' According to the chapter 11 bankruptcy filings, Sunnova faced 'critically tight liquidity' and expected to run out of cash this April or May if it was unable to secure additional financing. However, the company's efforts to find new lenders earlier this year were unsuccessful, a failure Mathews partially attributed in court documents to uncertainty created by Trump's executive order to freeze spending authorized by the Inflation Reduction Act. Although the courts have paused the implementation of that executive order and restored payouts under the act, the uncertainty it created meant lenders were unwilling to provide Sunnova with additional financing, Mathews said. He also said that although Sunnova grew its revenues and quadrupled its customer count between 2020-2024, market factors such as above-target inflation, prolonged high interest rates and tariffs had diminished the company's profitability. The company attempted to cut costs and free up funds to make its growing debt service payments by focusing on lower-risk installations, and by 2025 had shrunk year-over-year net losses by more than 10%, Mathews said. The company also installed new leadership, including Mathews, and laid off 50% of its workforce earlier this year. However, the new strategy was unable to make up for its previous policy of aggressive spending and borrowing in pursuit of rapid growth. By early 2025 the company was unable to pay its dealer network, which caused its contractors to stop work on projects that were in process and further curtailed the company's incoming cash flows, Mathews said. Recommended Reading Utilities' misguided opposition to community solar in California Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
13 minutes ago
- Yahoo
China affirms trade deal with US, says it always keeps its word
BEIJING (Reuters) -China on Thursday affirmed a trade deal announced by U.S. President Donald Trump, saying both sides needed to abide by the consensus and adding China always kept its word. The deal, reached after Trump and China's President Xi Jinping spoke on the telephone last week, brings a delicate truce in a trade war between the world's two largest economies. "China has always kept its word and delivered results," Lin Jian, a foreign ministry spokesperson, said at a regular news conference. "Now that a consensus has been reached, both sides should abide by it." The Trump-Xi telephone call broke a standoff that had flared just weeks after a preliminary deal was reached in Geneva. The call was quickly followed by more talks in London that Washington said had put "meat on the bones" of the Geneva agreement to ease bilateral retaliatory tariffs. The Geneva deal had faltered over China's continued curbs on minerals exports, prompting the Trump administration to respond with export controls preventing shipments of semiconductor design software, jet engines for Chinese-made planes and other goods to China. Trump on Wednesday said he was very happy with the trade deal. "Our deal with China is done, subject to final approval with President Xi and me," Trump said on Truth Social. "Full magnets, and any necessary rare earths, will be supplied, up front, by China. Likewise, we will provide to China what was agreed to, including Chinese students using our colleges and universities (which has always been good with me!). We are getting a total of 55% tariffs, China is getting 10%." Still, specifics of the latest deal and details on how it will be implemented remain unclear. A White House official said the 55% represents the sum of a baseline 10% "reciprocal" tariff Trump has imposed on goods imported from nearly all U.S. trading partners, 20% on all Chinese imports associated with his accusation that China had not done enough to stem the flow of fentanyl into the U.S., and pre-existing 25% levies on imports from China put in place during Trump's first presidential term. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
23 minutes ago
- Yahoo
Fapon Biopharma to Showcase Differentiated Pipeline, Including Phase 1 Immunocytokine FP008, and Innovative Technology Platforms at BIO 2025
BOSTON, June 12, 2025 /PRNewswire/ -- Fapon Biopharma, a clinical-stage biotech company innovating therapeutic antibodies and fusion proteins, is pleased to announce its participation in the BIO International Convention 2025 (BIO 2025), taking place June 16-19 in Boston Convention & Exhibition Center. The company will exhibit at Booth #1851, presenting its differentiated pipeline, including the flagship Phase 1 immunocytokine FP008, a portfolio of promising early-stage candidates for oncology and autoimmune diseases, and its suite of proprietary technology platforms, while actively seeking global partnerships. FP008, Fapon Biopharma's lead asset, is a first-in-class immunocytokine currently in Phase 1 clinical trials, designed to address significant unmet needs in solid tumor patient refractory to anti-PD-1 therapy. The company will also feature promising preclinical candidates targeting oncology (FP010, FP011, FPE021) and autoimmune diseases (FPE022, FPE024), highlighting its expanding research capabilities. Fapon Biopharma will feature its proprietary and innovative technology platforms, engineered to overcome complex drug development challenges: Bi/Tri-TCE Platform: Human-monkey cross-reactive TCR/CD3 nanobody, enabling the design of potent multi-specific antibodies for targeted cancer immunotherapy. FILTEN™ (IL-10M Fusion Protein Platform): Overcoming IL-10 limitations for broad applications in cancer and autoimmune diseases PROTiNb™ (Proteolysis Targeting Intra-Nanobody): A pioneering platform targeting previously "undruggable" intracellular targets, demonstrating a strong competitive edge. FIND™ Mammalian Cell Display Platform: Accelerating antibody discovery by combining mammalian cell expression with high-throughput screening. "We are excited to connect with the global biopharma community at BIO 2025," said Vincent Huo, President of Fapon Biopharma. "We look forward to demonstrating the exciting progress of our internal pipeline and how our technology platforms can empower external partners to bring transformative therapy to patients faster." Engagement Opportunities:Exhibition Booth: #1851Company Presentation: Time: 11:30 a.m., Tuesday, June 17, 2025Location: Room 153A, Boston Convention & Exhibition Center To schedule a meeting in advance or during the conference, please contact our BD representatives, Max Wang ( and Liyan Gao ( or visit us at Booth #1851. Meetings can also be requested via the BIO partnering system. About Fapon Biopharma ( Fapon Biopharma specializes in discovering and developing biologics for treating cancers, autoimmune diseases and other diseases where there are unmet medical needs. Leveraging cutting-edge technologies, we have built advanced drug discovery platforms, including an antibody discovery platform based on the globally leading mammalian cell display technology, a platform for generating IL-10M fusion proteins, and a platform for developing multispecific antibodies using Fibody and nanobodies. With a differentiated pipeline of leading drug candidates, we have established capabilities that cover the entire drug development process from drug discovery, preclinical research, Chemistry, Manufacturing and Controls (CMC) to early clinical development. Committed to innovation, we strive to deliver safer, more efficacious, affordable, and accessible biologics for everyone. View original content to download multimedia: SOURCE Fapon Biopharma Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
